Key facts
- This page summarizes PERCEPTIVE ADVISORS LLC's Form 4 filing for Adagio Medical Holdings, Inc. (ADGM).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 14 Feb 2025, 16:35.
PERCEPTIVE ADVISORS LLC - 22 Jan 2025 Form 4 Insider Report for Adagio Medical Holdings, Inc. (ADGM)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- ADGM
- Reported as of
- 22 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Feb 2025, 16:35:06 UTC
- Prior SEC filing
- 14 Aug 2024
- Next SEC filing
- 21 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
PERCEPTIVE ADVISORS LLC filed Form 4 for Adagio Medical Holdings, Inc. (ADGM) on 14 Feb 2025.
Change
- Previous filing in this sequence was filed on 14 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADGM
transaction
Common Stock
Award
- Transaction value
- Shares
- +64,167
- Change %
- +0.67%
- Price
- Shares after
- 9,675,684
- Date
- 22 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
ADGM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 200,902
- Date
- 22 Jan 2025
- Ownership
- See footnote
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On January 22, 2025, the Reporting Persons were issued 64,167 shares of Common Stock of the Issuer at a price of $2.00 per share pursuant to the terms of the Convert Waiver, dated December 26, 2024, by and between the Issuer and the Reporting Persons in exchange for the waiver by the Reporting Persons of certain rights related to the Issuer's default under its Senior Secured Convertible Notes.
Footnote F2
The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman ("Mr. Edelman") serves as the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of their indirect pecuniary interest therein, and this report shall not be deemed an admission that the Advisor or Mr. Edelman are beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Footnote F3
Directly held by C2 Life Sciences LLC ("C2"). The Advisor serves as the investment manager to C2.